01222018Headline:

Southeast Pennsylvania, Pennsylvania

HomePennsylvaniaSoutheast Pennsylvania

    Heading
    • Nuedexta: Did Greed Push this Pill’s Popularity?

      Nuedexta: Did Greed Push this Pill’s Popularity?

      Avanir Pharmaceuticals manufactures Nuedexta, a prescription drug medication approved by the Food and Drug Administration (FDA) to treat a rare condition—pseudobulbar affect (PBA)—where sufferers experience uncontrollable laughing and crying. Yet, a recent CNN investigation has found that doctors increasingly are […]

    • New Study Says Heart Stents Are Ineffective for Pain

      New Study Says Heart Stents Are Ineffective for Pain

      According to the Centers for Disease Control and Prevention (CDC), about 735,000 people suffer a heart attack each year in the U.S.—making heart disease the leading cause of death in America. Since the mid-1980s when the first coronary stent was […]

    • Could New FDA Commissioner Lift Drug Label Restrictions?

      Could New FDA Commissioner Lift Drug Label Restrictions?

      While the Food and Drug Administration (FDA) is charged with supervising a wide array of public health concerns that include blood transfusions, radiation-emitting devices, tobacco products and even cosmetics, many know the government agency for the regulation of prescription and […]

    • Risperdal Trials Set for Next Month as Number of New Cases Continues to Grow

      Risperdal Trials Set for Next Month as Number of New Cases Continues to Grow

      Mass tort cases continue to pile up for Johnson & Johnson (J&J) and their subsidiaries.  So is the case with Risperdal, a treatment for bipolar disorder and schizophrenia that was first approved by the Food and Drug Administration (FDA) in […]

    • Most Recent VW Defect Could Compromise Handling and Overall Safety

      Most Recent VW Defect Could Compromise Handling and Overall Safety

      Almost two years since VW’s dieselgate first hit the fan, new class action litigation hints that problems still linger for the German automaker. The most recent allegations involve the CC Sport (marketed as a non-sports car with sports car-like handling) […]

    • Why Isn’t the FDA More Concerned about Actemra?

      Why Isn’t the FDA More Concerned about Actemra?

      Actemra (tocilizumab) is a drug used to treat moderate to severe rheumatoid arthritis (RA). RA affects over 1.5 million people in the U.S. and women are three times more likely than men to get this disease. RA is a progressive, […]

    • Mass Tort Actions Will Not Be Deterred by U.S. Supreme Court Ruling

      Mass Tort Actions Will Not Be Deterred by U.S. Supreme Court Ruling

      The U.S. Supreme Court ruled this month on a California court case concerning lawsuits against Bristol-Myers Squibb’s (BMS) Plavix blood thinner that could impact how drug and device litigation moves forward in state courts. Voting 8-1, the Justices said that […]

    • Invokana Called into Question with Latest FDA Warning

      Invokana Called into Question with Latest FDA Warning

      When Invokana was first approved by the Food and Drug Administration (FDA) in 2013, it commenced a new class of diabetes treatment. Specifically known as an SGLT2 inhibitor, canagliflozin—the trade name of Janssen Pharmaceuticals’ Invokana—was the first drug of its […]

    • When Did MoM Hip Manufacturer DePuy Know their Product Was Defective?

      When Did MoM Hip Manufacturer DePuy Know their Product Was Defective?

      Documents have recently surfaced during an investigation by The Daily Telegraph in Great Britain that show experts, both outside of and within the company, had warned DePuy of problems with their metal-on-metal hip design—going back as far as 1995. According […]

    • Hernia Mesh Cases Move Forward with MDL

      Hernia Mesh Cases Move Forward with MDL

      In December, I wrote a blog discussing the likelihood of MultiDistrict Litigation (MDL) for two manufacturers of a hernia mesh surgical device—Atrium Medical who produces C-Qur mesh and Ethicon, Inc., a subsidiary of Johnson & Johnson, who recalled their Physiomesh […]